Atara Biotherapeutics Inc ATRA:NASDAQ

Last Price$17.72Cboe Real-Time Last Sale as of 2:24PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.17(0.95%)
Bid (Size)$17.71 (13)
Ask (Size)$17.76 (100)
Day Low / High$17.64 - 18.61
Volume290.0 K
 

View Biotechnology IndustryPeer Comparison as of 12/01/2021

 

Atara Biotherapeutics Inc ( NASDAQ )

Price: $17.72
Change: -0.17 (0.95%)
Volume: 290.0 K
2:24PM ET 12/01/2021
 
 

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $24.17
Change: -0.26 (1.06%)
Volume: 169.6 K
2:25PM ET 12/01/2021
 
 

Protagonist Therapeutics Inc ( NASDAQ )

Price: $32.01
Change: -1.61 (4.79%)
Volume: 362.6 K
2:25PM ET 12/01/2021
 
 

Iveric Bio Inc ( NASDAQ )

Price: $14.50
Change: -0.12 (0.82%)
Volume: 954.1 K
2:24PM ET 12/01/2021
 
 

Alector Inc ( NASDAQ )

Price: $20.71
Change: +0.06 (0.29%)
Volume: 196.6 K
2:24PM ET 12/01/2021
 

Read more news Recent News

Insider Sell: Atara Biotherapeutics
5:33PM ET 11/17/2021 MT Newswires

Joe Newell, Chief Operations Officer, on November 15, 2021, sold 7,000 shares in Atara Biotherapeutics (ATRA) for $124,004. Following the Form 4 filing...

Insider Sell: Atara Biotherapeutics
5:03PM ET 11/05/2021 MT Newswires

Matthew K Fust, Director, on November 04, 2021, sold 13,354 shares in Atara Biotherapeutics (ATRA) for $260,403. Following the Form 4 filing with the SEC,...

Atara Biotherapeutics Reports Narrower Q3 Loss
11:15AM ET 11/04/2021 MT Newswires

Atara Biotherapeutics (ATRA) said Thursday its Q3 net loss narrowed to $0.90 per diluted share from $0.92 a year earlier. Analysts were looking for a...

Sector Update: Health Care Stocks Slide This Afternoon
4:03PM ET 10/04/2021 MT Newswires

Health care stocks were finishing slightly above their worst levels of Monday trading, with the NYSE Health Care Index falling 1.2% this afternoon while...

Company Profile

Business DescriptionAtara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA. View company web site for more details
Address611 Gateway Boulevard
South San Francisco, California 94080
Phone+1.650.278.8930
Number of Employees311
Recent SEC Filing11/26/2021424B5
President, Chief Executive Officer & DirectorPascal Touchon
Chief Operating Officer & Executive Vice PresidentJoseph Newell
Chief Financial Officer & Senior Vice PresidentUtpal Koppikar
Chief Medical OfficerManher AJ Joshi

Company Highlights

Price Open$18.05
Previous Close$17.89
52 Week Range$11.81 - 28.20
Market Capitalization$1.6 B
Shares Outstanding88.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.62
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-2,564.88%
Return on Equity-87.32%

Analyst Ratings as of 08/24/2021

Buy
9
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset